ASCO膀胱癌研究进展及 EAU睾丸癌指南简介.pptx

ASCO膀胱癌研究进展及EAU睾丸癌指南简介;男性癌症死亡率，结直肠癌、胰腺癌、前列腺癌、白血病上升，肺癌、膀胱癌和脑瘤保持稳定。;【肿瘤流行病学】;

新辅助化疗/辅助化疗标准方案：

DDMVAC（MTX、VBL、ADM、DDP）生长因子支持，3-4周期

GP（GEM+DDP）4周期

CMV（DDP、MTX、VBL）3周期;晚期

一线：

如果可以用顺铂，标准方案：GP、DDMVAC

如果由于肾功能或PS评分限制，不能用顺铂，推荐GC（GEM+CBP)；备选：

GEM;GEM+PAX

如果由于听神经限制，但肾功能和PS评分较好，推荐IFO+ADM+GEM

二线：

推荐：PAX或DOC;GEM;PEM；备选：Nab-PAX、IFO、MTX、IFO+ADM+GEM、

GEM+PAX、GP、DDMVAC;2015ASCO;Effectivenessofadjuvantchemotherapy(AC)versusobservationinpatientswith≥pT3and/orpN+bladdercancer(Bca);APhaseIaStudyofAtezolizumab(MPDL3280A/Anti-PDL1):br/UpdatedResponseandSurvivalDatabr/inUrothelialBladderCancer(UBC);Atezolizumab(MPDL3280A)IsaHumanizedAnti-PDL1Anti-bodyThatInhibitstheBindingofPD-L1toPD-1andB7.1;Atezolizumab(MPDL3280A):PhaseIaStudy;Atezolizumab(MPDL3280A):BaselineCharacteristicsbr/inUBC(safetyevaluable);Atezolizumab(MPDL3280A):BaselineCharacteristicsbr/inUBC(safetyevaluable);Atezolizumab(MPDL3280A):BaselineCharacteristicsbr/inUBC(safetyevaluable);Atezolizumab(MPDL3280A):BaselineCharacteristicsbr/inUBC(safetyevaluable);Atezolizumab(MPDL3280A):BaselineCharacteristicsbr/inUBC(safetyevaluable);Atezolizumab(MPDL3280A):BaselineCharacteristicsbr/inUBC(safetyevaluable);;Atezolizumab(MPDL3280A):ORRinUBCbyICStatus;Atezolizumab(MPDL3280A):ResponseinUBCbr/byICstatus;;Atezolizumab(MPDL3280A):SurvivalinUBC;Atezolizumab(MPDL3280A):PhaseIaUBCSummary;Pembrolizumab(MK-3475)forAdvancedUrothelialCancer:UpdatedResultsandBiomarkerAnalysisfromKEYNOTE-012;PD-1PathwayandImmuneSurveillance;Pembrolizumab(MK-3475)br/HumanizedIgG4,High-Affinity,Anti-PD-1Antibody;KEYNOTE-012(NCbr/PhaseIbMulti-CohortStudyofPembrolizumabinPatientsbr/WithPD-L1PositiveAdvancedSolidTumors;KEYNOTE-012:UrothelialCohort;BaselineCharacteristics;Treatment-RelatedAdverseEvents;AEsofInterestBasedOnImmuneEtiology;AntitumorActivity;MaximumPercentChangeFromBaselinebr